U.S. flag An official website of the United States government
  1. Home
  2. Drugs
  3. News & Events for Human Drugs
  4. Drug Permeability: Best Practices for Biopharmaceutics Classification System-Based Biowaivers - 12/06/2021
  1. News & Events for Human Drugs

Workshop | Virtual

Event Title
Drug Permeability: Best Practices for Biopharmaceutics Classification System-Based Biowaivers
December 6, 2021


December 6, 2021


December 6, 2021 


8:30 a.m. to 4:20 p.m. 



The Food and Drug Administration (FDA) and the University of Maryland Center of Excellence in Regulatory Science and Innovation (M-CERSI) are announcing a virtual public workshop entitled "Drug Permeability: Best Practices for Biopharmaceutics Classification System-Based Biowaivers." 

The Biopharmaceutics Classification System (BCS) is a well-established scientific framework based on solubility and permeability of the drug substance, plus dissolution of the drug product, and provides assurance of in vivo bioequivalence based on extensive in vitro comparative characterization. As a result, BCS provides a pathway to avoid unnecessary human studies. Recommendations for BCS-based biowaivers were finalized in 2019 in the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) M9 guidance Biopharmaceutics Classification System-Based Biowaivers (https://go.usa.gov/xeqjA). 

Within BCS, the most difficult criterion to establish is that the drug substance is highly permeable, as it requires fundamental human mass-balance or absolute bioavailability studies, or extensive in vitro cell permeability data using a properly validated system. The purpose of this workshop is to discuss the industry, academic, and regulatory experience in generating and evaluating permeability data which will further facilitate the implementation of BCS and the efficient development of high-quality drug products globally. 

In addition to lectures and a panel discussion, this workshop will include parallel breakout sessions on permeability methods, excipient effects, and use of label and literature, respectively. These breakout sessions aim to allow attendees to comment on scientific issues. These breakout sessions (1 hour in duration) will occur at 2:00 p.m. ET and are repeated at 3:00 p.m. ET.  When registering, participants will be able to indicate their two preferred breakout sessions. 

Breakout sessions are as follows: 

  • Breakout session 1: In vitro and in silico intestinal permeability methods 
  • Breakout session 2: Excipient effects on permeability, do we need to be concerned? 
  • Breakout session 3: Use of label and literature data to designate permeability class 

Meeting Information and Registration: 

This workshop is open to the public; The workshop agenda can be found at: https://cersi.umd.edu/event/16683/drug-permeability-best-practices-for-bcs-based-biowaivers


If you have any additional questions about this workshop, please contact: 

Mehul Mehta, PhD 

Office of Clinical Pharmacology 

Center for Drug Evaluation and Research 

Food and Drug Administration,  

10903 New Hampshire Ave., Silver Spring, MD  20993-0002 


Back to Top